Albumin-binding photosensitizer capable of targeting glioma via the SPARC pathway

BACKGROUND: Malignant glioma is among the most lethal and frequently occurring brain tumors, and the average survival period is 15 months. Existing chemotherapy has low tolerance and low blood-brain barrier (BBB) permeability; therefore, the required drug dose cannot be accurately delivered to the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xingshu, Oh, Jae Sang, Lee, Yoonji, Lee, Eun Chae, Yang, Mengyao, Kwon, Nahyun, Ha, Tae Won, Hong, Dong-Yong, Song, Yena, Kim, Hyun Kyu, Song, Byung Hoo, Choi, Sun, Lee, Man Ryul, Yoon, Juyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031904/
https://www.ncbi.nlm.nih.gov/pubmed/36945032
http://dx.doi.org/10.1186/s40824-023-00360-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031904/
https://www.ncbi.nlm.nih.gov/pubmed/36945032
http://dx.doi.org/10.1186/s40824-023-00360-3

Ejemplares similares